Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder

(MedPage Today) -- SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy. From baseline to 24 weeks...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news